Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Charu Aggarwal, MD, MPH

Charu Aggarwal, MD, MPH Physician

Leslye M. Heisler Assistant Professor for Lung Cancer Excellence

Dr. Aggarwal is employed by Penn Medicine.

About Dr. Charu Aggarwal

Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer. Her clinical research focus is on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapy approaches including cellular therapy and CAR-T for solid tumors.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2011
  • Medical Oncology, 2011

Clinical Expertise:

  • Adenocarcinoma of Lung
  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Cancer of the Hard/Soft Palate
  • Cancer of the Nasal Cavity
  • Cancer of the Parotid
  • Cancer of the Supraglottis
  • Cancer of the Vocal Cords
  • Chemoradiation
  • Combined Modality Therapy
  • Ear and Temporal Bone Tumors
  • EGFR Mutation
  • Glottic Cancer
  • Hypopharyngeal Cancer
  • Immunotherapy
  • Jaw Cancer
  • Kras Mutation
  • Large Cell Cancer of the Lung
  • Laryngeal Cancer
  • Medullary Cancer of Thyroid
  • Metastatic Squamous Neck Cancer with Occult Primary
  • Mouth Cancer (Oral Cancer)
  • Nasal Cavity and Paranasal Sinus Cancer
  • Nasopharyngeal Cancer
  • Neck Cancer
  • Non-Small Cell Lung Cancer
  • Oropharyngeal Cancer
  • Salivary Gland Cancer
  • Small Cell Lung Cancer
  • Squamous Cancer of the Lung
  • Squamous Cell Carcinoma of the Head and Neck
  • Squamous Cell Carcinoma of the Jaw
  • Squamous Cell Carcinoma of the Mouth
  • Squamous Cell Carcinoma of the Throat
  • Squamous Cell Carcinoma of the Tonsils
  • Thoracic Cancer
  • Throat Cancer
  • Tongue Cancer
  • Tonsil Cancer
  • Tumor of Parotid Gland
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Lady Hardinge Medical College
Residency: SUNY at Buffalo Medical Center
Fellowship: Fox Chase Cancer Center

Memberships

American Association of Cancer Research, National American Society of Clinical Oncology, National Eastern Cooperative Oncology Group, National International Association for the Study of Lung Cancer, International National Cancer Institute (NCI), National

Hospital Affiliation

Dr. Aggarwal is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Dr. Aggarwal is the Leslye Heisler Assistant Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania’s Perelman School of Medicine. She is an active member of the Abramson Cancer Center (ACC) where she serves as Physician Leader for the clinical research program for Airways Malignancies.

Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer, with a specific and clinical research focus on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principle investigator for multiple clinical trials focusing on the development of “targeted” immunotherapeutic approaches including cellular therapy and CAR-T for solid tumors. Dr. Aggarwal has led the development of a DNA plasmid based HPV specific immunotherapy for HPV associated head and neck cancers. She is actively involved in evaluating the role of plasma-based NGS in management of patients with metastatic lung cancer.

She has extensive experience in the planning, design and execution of clinical trials, is an active member of ECOG, and has served as a national sub-study chair for SWOG-NCI’s LUNG-MAP. She has served on the Annual Meeting Scientific Program Committee of American Society of Clinical Oncology (ASCO), ASCO Education Committee, NCI- Head and Neck Metastatic Task Force Steering Committee and ACC’s Data Safety and Monitoring Committee. Dr. Aggarwal’s ultimate goal as a clinical and translational investigator is to perform patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung and Head and Neck Cancer.

Selected Publications:

Gershowitz J, Chao HH, Doucette A, Lukens JN, Swisher-McClure S, Weinstein GS, O'Malley BW Jr, Chalian AA, Rassekh CH, Newman JG, Cohen RB, Bauml JM, Aggarwal C, Lin A: Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer Br J Radiol doi: 10.1259/bjr.20190466 : 2019.

Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer C, Feigenberg SJ, Berman AT: Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC Int J Radiat Oncol Biol Phys : pii: S0360-3016(19)33901-X,,2019.

Balata H, Fong KM, Hendriks LE, Lam S, Ostroff JS, Peled N, Wu N, Aggarwal C: Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 J Thorac Oncol 14 (9): 1513-1527,2019.

Chao HH, Schonewolf CA, Tan EX, Swisher-McClure S, Ghiam AF, Weinstein GS, O'Malley BW Jr, Chalian AA, Rassekh CH, Newman JG, Cohen RB, Bauml JM, Aggarwal C, Lin A, Lukens JN: The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiation Head Neck : 2019.

Bauml JM, Aggarwal C, Cohen RB: Immunotherapy for head and neck cancer: where are we now and where are we going? Annals of Translational Medicine : (Suppl 3):S75. doi: 10.21037/atm.2019.03.58,2019.

Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ.: Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol : 2019.

Beck TN, Boumber YA, Aggarwal C, Pei J, Thrash-Bingham C, Fittipaldi P, Vlasenkova R, Rao C, Borghaei H, Cristofanilli M, Mehra R, Serebriiskii I, Alpaugh RK.: Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. BMC Cancer 19 (1): 603,2019.

Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR.: Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. S1556-0864 (19): 30462-9,2019.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.: Five-Year Overall Survival for Patients With Advanced Non Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. : 2019.

Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA: Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. S1556-0864 (19): 30414-9,2019.

Academic Contact Info

Perelman Center for Advanced Medicine
10-137, South Pavilion
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 662-6318
Patient appointments: 800-789-7366 (PENN)